Aligos Therapeutics, Inc.

Katholieke Universiteit Leuven

Alios Biopharma, Inc.

Janssen Biopharma, Inc.

Janssen Pharmaceutica Nv

Intermune, Inc.

Antitsa Dimitrova Stoycheva

Leonid Beigelman

Pierre Jean-Marie Bernard Raboisson

Robert Than Hendricks

David Bernard Smith

Koen Vandyck

Jerome Deval

Dorothée Alice Marie-Eve Bardiot

Arnaud Didier Marie Marchand

Sandro Boland

Tongfei Wu

Francois Gonzalvez

Cheng Liu

Sergei M Gryaznov

Yi Jin

Vivek Kumar Rajwanshi

Vladimir Serebryany

Rajendra K Pandey

Bharat Baral

Lakshmipathi Pandarinathan

David Craig McGowan

Brad Owen Buckman

Jean-François Bonfanti

Scott D Seiwert

Jérôme Michel Claude Fortin

Williamson Ziegler Bradford

Sandrine Vendeville

Jin Hong

Guillaume Jean Maurice Mercey

Yannick Debing

Santhosh Kumar Thatikonda

Steven B Porter

Sarah Katherine Stevens

Saul Martinez Montero

Qingling Zhang

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Anti-viral compounds

Modified oligonucleotides comprising modifications at the 2' and/or 3′ position(s) along with methods of making and use, e.g., against HBV are disclosed.

Modified oligonucleotides and methods of use

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

Methods and compositions for targeting PD-L1

Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B

Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), Formula (II) and/or Formula (III), or a pharmaceutically acceptable salt of any of the foregoing.

Modified cyclic dinucleoside compounds as sting modulators

The present invention relates to macrocyclic pyridotriazine derivatives of formula (I) and the pharmaceutically acceptable salts, solvates or polymorph thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family.

Macrocyclic flu endonuclease inhibitors

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

Aza-pyridone compounds and uses thereof

Modified oligonucleotides comprising modifications at the 2' and/or 3&#x2032; positions(s) along with methods of making and use, e.g., against HBV are disclosed.

AZA-pyridone compounds and uses thereof

Disclosed herein are pyridazinone compounds, pharmaceutical compositions that include one or more pyridazinone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with a pyridazinone compounds. Examples of an orthomyxovirus viral infection includes an influenza infection.

Pyridazinone compounds and uses thereof

Growing community of inventors

Half Moon Bay, CA, United States of America

Antitsa Dimitrova Stoycheva